Attached files
| file | filename |
|---|---|
| EX-10.13H - EXHIBIT 10.13(H) - Anika Therapeutics, Inc. | ex_231634.htm |
| EX-10.13G - EXHIBIT 10.13(G) - Anika Therapeutics, Inc. | ex_231633.htm |
| EX-10.13E - EXHIBIT 10.13(E) - Anika Therapeutics, Inc. | ex_231632.htm |
| EX-10.13D - EXHIBIT 10.13(D) - Anika Therapeutics, Inc. | ex_231631.htm |
| EX-32.1 - EXHIBIT 32.1 - Anika Therapeutics, Inc. | ex_231250.htm |
| EX-31.2 - EXHIBIT 31.2 - Anika Therapeutics, Inc. | ex_231249.htm |
| EX-31.1 - EXHIBIT 31.1 - Anika Therapeutics, Inc. | ex_231248.htm |
| 10-K - FORM 10-K - Anika Therapeutics, Inc. | anik20201231_10k.htm |
EXHIBIT 23.1
CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
We consent to the incorporation by reference in Registration Statements on Form S-8 (Nos. 333-110326, 333-160102, 333-176103, 333-190597, 333-219190, 333-232254 and 333-239304) of Anika Therapeutics, Inc. of our reports dated March 5, 2021, relating to the financial statements of Anika Therapeutics, Inc. (the “Company”), and the effectiveness of the Company's internal control over financial reporting, appearing in this Annual Report on Form 10-K of Anika Therapeutics, Inc. for the year ended December 31, 2020.
/s/ Deloitte & Touche LLP
Boston, Massachusetts
March 5, 2021